| Migraine Disorders
Cambia vs VYEPTI
Side-by-side clinical, coverage, and cost comparison for migraine disorders.Deep comparison between: Cambia vs Vyepti with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsVyepti has a higher rate of injection site reactions vs Cambia based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Vyepti but not Cambia, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Cambia
Vyepti
At A Glance
Oral
Single dose
NSAID
IV infusion
Every 3 months
CGRP antagonist
Indications
- Migraine Disorders
- Migraine Disorders
Dosing
Migraine Disorders One packet (50 mg) dissolved in 1 to 2 ounces (30 to 60 mL) of water, taken orally as a single dose on an empty stomach for best effectiveness; use the lowest effective dose for the shortest duration consistent with individual patient treatment goals.
Migraine Disorders 100 mg by IV infusion every 3 months; some patients may benefit from 300 mg by IV infusion every 3 months.
Contraindications
- Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac or any components of the drug product
- History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs
- In the setting of coronary artery bypass graft (CABG) surgery
- Serious hypersensitivity to eptinezumab-jjmr or any excipient, including anaphylaxis and angioedema
Adverse Reactions
Most common (>=1%) Nausea, dizziness
Serious Cardiovascular thrombotic events, GI bleeding/ulceration/perforation, hepatotoxicity, hypertension, heart failure and edema, renal toxicity and hyperkalemia, anaphylactic reactions, serious skin reactions, DRESS, medication overuse headache, hematologic toxicity
Postmarketing GI reactions (abdominal pain, constipation, diarrhea, dyspepsia, nausea, ulcers, vomiting), abnormal renal function, anemia, dizziness, edema, elevated liver enzymes, headaches, increased bleeding time, pruritus, rashes, tinnitus
Most common (>=2%) nasopharyngitis, hypersensitivity reactions
Postmarketing anaphylaxis, fatigue, hypertension, Raynaud's phenomenon
Pharmacology
NSAID that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis in peripheral tissues; analgesic, anti-inflammatory, and antipyretic properties are attributed to this decrease in prostaglandins, which sensitize afferent nerves and mediate inflammation.
Eptinezumab-jjmr is a humanized IgG1 monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor, thereby preventing CGRP-mediated effects relevant to migraine.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Cambia
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (0/12)
Vyepti
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Cambia
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Vyepti
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Cambia
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Vyepti
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Cambia.
Cost estimate not availableHealthWell: Migraine
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CambiaView full Cambia profile
VyeptiView full Vyepti profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.